Irritable bowel syndrome: A clinical review

JAMA - Journal of the American Medical Association

Volumn 313, Issue 9, 2015, Pages 949-958

  Chey, William D ^a   Kurlander, Jacob ^a   Eswaran, Shanti ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; LAXATIVE; LOPERAMIDE; LUBIPROSTONE; ONDANSETRON; PEPPERMINT OIL; PROBIOTIC AGENT; RIFAXIMIN; SEROTONIN 3 ANTAGONIST; SPASMOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GASTROINTESTINAL AGENT; SEROTONIN ANTAGONIST;

ACUPUNCTURE; ALTERNATIVE MEDICINE; DIAGNOSTIC TEST; DIET THERAPY; DIETARY FIBER; DRUG RESPONSE; FAMILY HISTORY; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTESTINE FLORA; INTESTINE MOTILITY; INTESTINE MUCOSA PERMEABILITY; IRON DEFICIENCY ANEMIA; IRRITABLE COLON; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MANAGED CARE; MUCOSAL IMMUNITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SOCIAL PSYCHOLOGY; SYMPTOM ASSESSMENT; SYSTEMATIC REVIEW; WEIGHT REDUCTION; COST OF ILLNESS; DIET; EXERCISE; IRRITABLE BOWEL SYNDROME; MICROFLORA;

COST OF ILLNESS; DIET; EXERCISE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MICROBIOTA; PARASYMPATHOLYTICS; SEROTONIN ANTAGONISTS;

EID: 84924455205     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.0954     Document Type: Review

References (91)

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: ameta-Analysis. Clin Gastroenterol Hepatol. 2012;10 (7): 712-721.e4.
2. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-Analysis. Am J Gastroenterol. 2012;107(7): 991-1000.
3. Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol. 2005;100(5): 1174-1184.
4. Riedl A, Schmidtmann M, Stengel A, et al. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. J Psychosom Res. 2008;64 (6): 573-582.
5. Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-Type symptoms in individuals with irritable bowel syndrome in the community: ameta-Analysis. Am J Gastroenterol. 2012;107(12): 1793-1801.
6. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-Analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010;8(5): 401-409.
7. Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-Analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8): 651-660.
8. El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: natural history of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;19(8): 861-870.
9. Engsbro AL, Simren M, Bytzer P. Short-Term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther. 2012;35 (3): 350-359.
10. Garrigues V, Mearin F, Badía X, et al; RITMO GROUP. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study). Aliment Pharmacol Ther. 2007;25(3): 323-332.
11. Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep. 2009;11(4): 265-269.
12. Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol. 2001;96(5): 1340-1349.
13. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States, part II: lower gastrointestinal diseases. Gastroenterology. 2009; 136(3): 741-754.
14. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am. 2011;40(1): 11-19.
15. SimrénM, Barbara G, Flint HJ, et al; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome Foundation report. Gut. 2013;62(1): 159-176.
16. Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther. 2014;39(10): 1033-1042.
17. Sainsbury A, Sanders DS, Ford AC. Prevalence of irritable bowel syndrome-Type symptoms in patients with celiac disease: ameta-Analysis. Clin Gastroenterol Hepatol. 2013;11(4): 359-365.e1.
18. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-Analysis. Am J Gastroenterol. 2012;107(10): 1474-1482.
19. Dai C, JiangM. The incidence and risk factors of post-infectious irritable bowel syndrome: ameta-Analysis. Hepatogastroenterology. 2012;59 (113): 67-72.
20. Öhman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7 (3): 163-173.
21. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46(4): 421-431.
22. Matricon J, Meleine M, Gelot A, et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther. 2012;36(11-12): 1009-1031.
23. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009;146(1-2): 41-46.
24. Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014;11(8): 497-505.
25. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and alteredmicrobiome. J NeurogastroenterolMotil. 2012;18(3): 258-268.
26. Eswaran S, Muir J, CheyWD. Fiber and functional gastrointestinal disorders. Am J Gastroenterol. 2013;108(5): 718-727.
27. Boettcher E, Crowe SE. Dietary proteins and functional gastrointestinal disorders. Am J Gastroenterol. 2013;108(5): 728-736.
28. Farré R, Tack J. Food and symptom generation in functional gastrointestinal disorders: physiological aspects. Am J Gastroenterol. 2013;108 (5): 698-706.
29. Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol. 2013;108(5): 707-717.
30. ParkMI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? a systematic review. Neurogastroenterol Motil. 2006;18(8): 595-607.
31. Drossman DA. Abuse, trauma, and GI illness: is there a link? Am J Gastroenterol. 2011;106(1): 14-25.
32. Chitkara DK, van TilburgMA, Blois-Martin N, Whitehead WE. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol. 2008;103(3): 765-774.
33. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med. 2011; 62: 381-396.
34. Tillisch K, Mayer EA, Labus JS. Quantitative meta-Analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology. 2011;140(1): 91-100.
35. Keefer L, Mandal S. The potential role of behavioral therapies in the management of centrally mediated abdominal pain. NeurogastroenterolMotil. doi: 10.1111/nmo.12474.
36. Longstreth GF, ThompsonWG, CheyWD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5): 1480-1491.
37. Saad RJ, Rao SS, Koch KL, et al. Do stool form and frequency correlate with whole-gut and colonic transit? results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol. 2010;105(2): 403-411.
38. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9): 920-924.
39. Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7(1): 68-72.
40. Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. Am J Gastroenterol. 2008;103(5): 1241-1248.
41. Brandt LJ, CheyWD, Foxx-Orenstein AE, et al; American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 (suppl 1): S1-S35.
42. Vanner SJ, DepewWT, PatersonWG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol. 1999;94(10): 2912-2917.
43. Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion? a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105(4): 848-858.
44. Ford AC, CheyWD, Talley NJ, Malhotra A, Spiegel BM, Moayyedi P. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-Analysis. Arch Intern Med. 2009; 169(7): 651-658.
45. Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology. 2011;141(4): 1187-1193.
46. Spiegel BM, DeRosa VP, Gralnek IM, Wang V, Dulai GS. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology. 2004;126(7): 1721-1732.
47. Macaigne G, Lahmek P, Locher C, et al. Microscopic colitis or functional bowel disease with diarrhea: a French prospective multicenter study. Am J Gastroenterol. 2014;109(9): 1461-1470.
48. CheyWD, Nojkov B, Rubenstein JH, Dobhan RR, Greenson JK, Cash BD. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 2010;105(4): 859-865.
49. Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol. 2014;12(2): 253-262.e2.
50. Menees SB, Kurlander J, Goel A, Powell CC, CheyWD. Meta-Analysis of the utility of common serum and fecal biomarkers in adults with IBS. Gastroenterology. 2014;146: S194.
51. Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11(10): 1270-1275.e1.
52. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30(7): 707-717.
53. Power AM, Talley NJ, Ford AC. Association between constipation and colorectal cancer: systematic review and meta-Analysis of observational studies. Am J Gastroenterol. 2013;108 (6): 894-903.
54. Guérin A, Mody R, Fok B, et al. Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation. Aliment Pharmacol Ther. 2014;40(1): 83-92.
55. Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol. 2014;109(8): 1141-1157, quiz 1058.
56. Ratuapli SK, Bharucha AE, Noelting J, Harvey DM, Zinsmeister AR. Phenotypic identification and classification of functional defecatory disorders using high-resolution anorectal manometry. Gastroenterology. 2013;144(2): 314-322.e2.
57. CheyWD, Baker JRB, Shifferd J. Assessment of abdominal symptoms before and after biofeedback therapy in patients with dyssynergic defecation. Am J Gastroenterol. 2012;107(suppl 1): S718.
58. Drossman DA. 2012 David Sun lecture: helping your patient by helping yourself-how to improve the patient-physician relationship by optimizing communication skills. Am J Gastroenterol. 2013;108 (4): 521-528.
59. Ford AC, Moayyedi P, Lacy BE, et al; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(suppl 1): S2-S26.
60. Song BK, Cho KO, Jo Y, Oh JW, Kim YS. Colon transit time according to physical activity level in adults. J Neurogastroenterol Motil. 2012;18(1): 64-69.
61. Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5): 915-922.
62. Hayes PA, Fraher MH, Quigley EM. Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol (N Y). 2014;10(3): 164-174.
63. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011;106(3): 508-514.
64. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013;144(5): 903-911.e3.
65. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145(2): 320-328.e1-3.
66. Murray K, Wilkinson-Smith V, Hoad C, et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol. 2014;109(1): 110-119.
67. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1): 67-75.e5.
68. Mawe GM, Hoffman JM. Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10(8): 473-486.
69. Chang L, CheyWD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol. 2006;101(5): 1069-1079.
70. Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63(10): 1617-1625.
71. Ruepert L, Quartero AO, deWit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;(8): CD003460.
72. CheyWY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol. 2001;96(5): 1499-1506.
73. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-Analysis. J Clin Gastroenterol. 2014;48(6): 505-512.
74. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-Analysis. Am J Gastroenterol. 2014;109(9): 1367-1374.
75. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013; 108(9): 1508-1515.
76. Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral bisacodyl is effective and well-Tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol. 2011;9(7): 577-583.
77. Lacy BE, CheyWD. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother. 2009;10 (1): 143-152.
78. Drossman DA, CheyWD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-Associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3): 329-341.
79. Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3', 5'-monophosphate. Gastroenterology. 2013;145(6): 1334-1346.
80. Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: ameta-Analysis. Clin Gastroenterol Hepatol. 2013;11(9): 1084-1092.e3.
81. CheyWD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11): 1702-1712.
82. Brenner DM, MoellerMJ, CheyWD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4): 1033-1049.
83. Menees S, ManeerattanapornM, CheyW. Efficacy of rifaximin in patients with irritable bowel syndrome: ameta-Analysis. Am J Gastroenterol. 2012;107(5): 28-35.
84. Salix Pharmaceuticals Inc. Salix's TARGET 3 study examines the safety and efficacy of repeat treatment with rifamixin 550mg for irritable bowel syndrome with diarrhea. http://news.salix.com/press-release/salixs-Target-3-study-examines-safety-And-efficacy-repeat-Treatment-rifaximin-550-mg. Accessed January 25, 2015.
85. Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-Analysis. Am J Gastroenterol. 2014;109(9): 1350-1365.
86. Dekel R, Drossman DA, Sperber AD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs. 2013;22(3): 329-339.
87. Drossman DA. Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol. 2009;104(12): 2897-2902.
88. Hunt MG, Moshier S, Milonova M. Brief cognitive-behavioral internet therapy for irritable bowel syndrome. Behav Res Ther. 2009;47(9): 797-802.
89. Ljótsson B, Hedman E, Andersson E, et al. Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial. Am J Gastroenterol. 2011;106(8): 1481-1491.
90. Hussain Z, Quigley EM. Systematic review: complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23(4): 465-471.
91. Manheimer E, Wieland LS, Cheng K, et al. Acupuncture for irritable bowel syndrome: systematic review and meta-Analysis. Am J Gastroenterol. 2012;107(6): 835-847.